UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Follow-Up Questions
What is Ucb SA (UCBJY)'s P/E Ratio?
The P/E ratio of Ucb SA is N/A
Who is the CEO of Ucb SA?
Mr. Jean-Christophe Tellier is the Chief Executive Officer of Ucb SA, joining the firm since 2011.
What is the price performance of UCBJY stock?
The current price of UCBJY is 120.04, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Ucb SA?
Ucb SA belongs to Pharmaceuticals industry and the sector is Health Care
What is Ucb SA market cap?
Ucb SA's current market cap is $45.6
Is Ucb SA a buy, sell, or hold?
According to wall street analysts, 24 analysts have made analyst ratings for Ucb SA, including 3 strong buy, 18 buy, 4 hold, 0 sell, and 3 strong sell
